Population variability in CD38 activity: Correlation with age and significant effect of TNF-伪 -308G > A and CD38 184C > G SNPs

详细信息	查看全文 | 推荐本文 |

• 作者：Valeria Polzonetti^a ; Francesco M. Carpi^a ; Daniela Micozzi^a ; Stefania Pucciarelli^a ; Silvia Vincenzetti^b ; Valerio Napolioni^a ; ^{valerio.napolioni@unicam.it}
• 关键词：Age ; CD38 ; NADase ; Enzyme activity ; Genetic polymorphism ; Tumor necrosis factor
• 刊名：Molecular Genetics and Metabolism
• 出版年：2012
• 期刊代码：175_10967192
• 类别：bio
• 出版时间：March, 2012
• 卷：105
• 期：3
• 页码：502-507
• 文件大小：338 K

摘要

CD38 (EC 3.2.2.6, NAD(+)-glycohydrolase) is a multifunctional enzyme catalyzing the synthesis and hydrolysis of cyclic ADP-ribose from NAD⁺ to ADP-ribose. The loss of CD38 function is associated with impaired immune responses, metabolic disturbances, and behavioral modifications. Notably, it has been linked to HIV infection, leukemias, myelomas, solid tumors, Type II Diabetes mellitus, bone metabolism, as well as Autism Spectrum Disorder. Taking into account the crucial role played by CD38 in many diseases and in clinical practice, here we assessed the distribution of CD38 NADase activity in a healthy population (104 sex-matched unrelated individuals, 12-98 years) and determined its main predictors among genetic and physiological factors (age and sex). The mean value of CD38 NADase activity was 0.051 卤 0.023 mU/mg (0.010-0.099 mU/mg), following a normal distribution in the study population (Kolmogorov-Smirnov test P = 0.200). The TNF-伪 -308G > A (rs1800629) resulted the main predictor (尾 = 0.364, P = 0.00008), followed by Age (尾 = 0.280, P = 0.002) and the CD38 184C > G (rs6449182) (尾 = 0.193, P = 0.033). Our study contributes to understanding CD38 enzyme physiological functions, by reporting, for the first time, its activity distribution in healthy individuals and demonstrating a significant positive correlation with age. Moreover, the possible use of TNF-伪 -308G > A (rs1800629) and the CD38 184C > G (rs6449182) SNPs as predictive genetic markers of CD38 activity, clearly point toward possible pharmacogenomic applications and to a more refined use of CD38 in clinical settings.